RecruitingPhase 1NCT06946641
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
Studying Cap myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
- Intervention
- QLS12010(drug)
- Enrollment
- 102 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Peking University Third Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06946641 on ClinicalTrials.govOther trials for Cap myopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07359287Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary CareUniversity Hospital, Caen
- RECRUITINGNANCT07325344Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility StudyShandong University
- ACTIVE NOT RECRUITINGNANCT07151261Ashwagandha for Nighttime WakingNational University of Natural Medicine
- RECRUITINGNANCT07268365Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ?Centre Hospitalier Universitaire, Amiens
- RECRUITINGPHASE2, PHASE3NCT07086313A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDOtsuka Pharmaceutical Co., Ltd.
- RECRUITINGPHASE4NCT07193277Butylphthalide for Cognitive Impairment in Elderly Patients With Focal EpilepsyFirst Affiliated Hospital of Wenzhou Medical University
- ACTIVE NOT RECRUITINGNCT06733337A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.Pfizer
- RECRUITINGPHASE3NCT06926829A Long-term Trial of EB-1020 in Adult Patients With ADHDOtsuka Pharmaceutical Co., Ltd.